PARP inhibition: Targeting the Achilles'heel of DNA repair to treat germline and sporadic ovarian cancers

Current Opinion in Oncology

Volumn 22, Issue 5, 2010, Pages 473-480

  Carden, Craig P ^a   Yap, Timothy A ^a   Kaye, Stan B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRCA1; BRCA2; homologous recombination; ovarian cancer; PARP inhibitors; targeted therapies

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOUBLE STRANDED DNA; DOXORUBICIN; GEMCITABINE; INO 1001; IRINOTECAN; KU 0058684; KU 0058948; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PF 01367338; SINGLE STRANDED DNA; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HISTOLOGY; HUMAN; MELANOMA; METASTASIS; MORTALITY; NAUSEA; NEUTROPENIA; ONCOLOGY; OVARY CANCER; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE STRANDED DNA BREAK; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; DNA REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77955415712     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833b5126     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-181.
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:6.
4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:4.
5. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921.
6. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25:5864-5874.
7. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-1078.
8. Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15:6314-6320.
9. Wooster R, Weber BL Breast and ovarian cancer. N Engl J Med 2003; 348:2339-2347.
10. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-695.
11. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66:1259-1272.
12. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676-689.
13. Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998; 17:3115-3124.
14. XuX, Weaver Z, LinkeSP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3:389-395.
15. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998; 1:347-357.
16. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20:4704-4716.
17. Kraakman-van Der Zwet M, Overkamp WJ, van Lange RE, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002; 22:669-679.
18. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26:882-893.
19. OttoH, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 2005; 6:139.
20. Noel G, Giocanti N, Fernet M, et al. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol 2003; 4:7.
21. Haber JE. DNA recombination: the replication connection. Trends Biochem Sci 1999; 24:271-275.
22. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4:511-518.
23. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7:263-272.
24. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88:265-275. (Pubitemid 28015875)
25. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-917.
26. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134. First clinical trial to demonstrate the antitumour activity of PARP inhibitors in BRCA mutation carriers.
27. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in brca carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol, 2010. [Epub ahead of print] doi:10.1200/JCO.2009.26.9589.
28. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-1115.
29. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451:111 6-1120.
30. Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68:2581-2586.
31. Ang JE, Yap TA, Fong PC, et al. Preliminary experience with the use of chemotherapy (CT) following disease progression on olaparib, a poly(ADP-Ribose) polymerase inhibitor (PARP-i) in ovarian cancer patients with germ-line BRCA mutations. ASCO Annual Meeting; 2010.
32. Audeh M, Penson R, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27:15s (suppl; abstr 5500).
33. Tan DS, Rothermundt C, Thomas K, et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26:5530-5536.
34. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-819.
35. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8:1 7.
36. Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethyla-tion in ovarian carcinoma: a population-based study. Cancer Res 2000; 60:5329-5333.
37. Palma JP, Rodriguez LE, Bontcheva-Diaz VD, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008; 28:2625-2635.
38. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-2737.
39. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolamide (TMZ) in patients with metastatic melanoma (MM). J Clin Oncol 2006; 35.
40. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG01 4699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917-7923.
41. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8:235-244.
42. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
43. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874.
44. Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008; 13:395-400.
45. Bedikian AY, Papadopoulos NE, Kim KB, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009; 27:756-763.
46. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcita-bine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27.
47. Hennessy B, Timms K, Carey MS, et al. Somatic BRCA status in ovarian tumours. J Clin Oncol 2009; 27:5528 [Suppl].
48. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128:157-170.
49. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40:102-107.
50. Mendes-Pereira A, Martin S, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Molec Med 2009; 1:1-8